In a report released yesterday, Dennis Ding from Jefferies maintained a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $18.00.
Dennis Ding has given his Buy rating due to a combination of factors that highlight Roivant Sciences’ potential for growth and value. One of the key reasons is the significant opportunity presented by the Graves’ disease market, which is often underestimated by investors. Roivant is strategically positioning itself to capitalize on this by targeting a patient pool with limited treatment options, potentially leading to substantial revenue given the expected pricing range.
Additionally, Roivant’s approach to FcRn indications shows a thoughtful strategy in selecting areas where they can lead or compete effectively, minimizing unnecessary R&D expenses. The ongoing litigation with Moderna regarding LNP technology is seen as having minimal risk, with potential for a favorable settlement that could significantly benefit Roivant. Lastly, the upcoming Phase III data for Brepo in dermatomyositis, despite its challenges, could drive stock value if successful, given the lack of approved therapies and potential for orphan drug pricing.
Ding covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Crinetics Pharmaceuticals, and Amicus. According to TipRanks, Ding has an average return of -8.0% and a 33.93% success rate on recommended stocks.